Red color represents old content. It may be empty showing addition in the new version.
Green color represents new content. It may be empty showing deletion in the new version.
Inline
Side by side
Added new contents,
deleted old contents,contents that are not changed.
New table contents
New table contents
Old table contents
Old table contents
Unchanged contents
Unchanged contents
Added new contents, contents that are not changed.
Deleted old contents, contents that are not changed.
Old table contents
Old table contents
Unchanged contents
Unchanged contents
New table contents
New table contents
Unchanged contents
Unchanged contents
Protocol summary
In this research, 56 eligible menopausal women who affected by atrophic vaginitis and over active bladder syndrome, referring to Ahar health centers will be chosen and will be randomly divided into two groups of control and intervention. Group allocation will be concealed by assigning a unique code to each participants.This trial is a study in Phase zero.
In this research, 72 eligible menopausal women who affected by atrophic vaginitis and over active bladder syndrome, referring to Tabriz health centers will be chosen and will be randomly divided into two groups of control and intervention. Group allocation will be concealed by assigning a unique code to each participants.This trial is a study in Phase zero.
In this research, 5672 eligible menopausal women who affected by atrophic vaginitis and over active bladder syndrome, referring to AharTabriz health centers will be chosen and will be randomly divided into two groups of control and intervention. Group allocation will be concealed by assigning a unique code to each participants.This trial is a study in Phase zero.
در این مطالعه 56 زن یائسه مبتلا به واژینیت آتروفیک و سندرم مثانه تحریک پذیر دارای شرایط ورود به مطالعه که به مراکز بهداشتی و درمانی شهر اهر مراجعه می کنند انتخاب می شوند. شرکت کنندگان بصورت تصادفی به دو گروه مداخله و کنترل تقسیم شده و به برای پنهان سازی گروه مداخله به هر یک از شرکت کنندگان یک کد اختصاص داده می شود. این مطالعه در فاز صفر کارآزمایی می باشد.
در این مطالعه 72 زن یائسه مبتلا به واژینیت آتروفیک و سندرم مثانه تحریک پذیر دارای شرایط ورود به مطالعه که به مراکز بهداشتی و درمانی شهر اهر مراجعه می کنند انتخاب می شوند. شرکت کنندگان بصورت تصادفی به دو گروه مداخله و کنترل تقسیم شده و به برای پنهان سازی گروه مداخله به هر یک از شرکت کنندگان یک کد اختصاص داده می شود. این مطالعه در فاز صفر کارآزمایی می باشد.
در این مطالعه 5672 زن یائسه مبتلا به واژینیت آتروفیک و سندرم مثانه تحریک پذیر دارای شرایط ورود به مطالعه که به مراکز بهداشتی و درمانی شهر اهر مراجعه می کنند انتخاب می شوند. شرکت کنندگان بصورت تصادفی به دو گروه مداخله و کنترل تقسیم شده و به برای پنهان سازی گروه مداخله به هر یک از شرکت کنندگان یک کد اختصاص داده می شود. این مطالعه در فاز صفر کارآزمایی می باشد.
The intervention group (receiving vitamin E vaginal cream containing 100 IU of vitamin E in half of the applicator) and control group (receiving conjugated estrogen vaginal cream with a dose of 0.625 mg in half of applicator containing 0.3 mg of conjugated estrogen), will use the half of the vaginal cream applicator deeply every night during the first week and two nights every week in the following weeks. The duration of the intervention will be eight weeks. The location of study will be in Ahar health centers.
The intervention group (receiving vitamin E vaginal cream containing 100 IU of vitamin E in half of the applicator) and control group (receiving conjugated estrogen vaginal cream with a dose of 0.625 mg in half of applicator containing 0.3 mg of conjugated estrogen), will use the half of the vaginal cream applicator deeply every night during the first week and two nights every week in the following weeks. The duration of the intervention will be eight weeks. The location of study will be in Tabriz health centers.
The intervention group (receiving vitamin E vaginal cream containing 100 IU of vitamin E in half of the applicator) and control group (receiving conjugated estrogen vaginal cream with a dose of 0.625 mg in half of applicator containing 0.3 mg of conjugated estrogen), will use the half of the vaginal cream applicator deeply every night during the first week and two nights every week in the following weeks. The duration of the intervention will be eight weeks. The location of study will be in AharTabriz health centers.
General information
56
72
5672
2022-01-21, 1400/11/01
2021-11-22, 1400/09/01
20222021-0111-2122 00:00:00
empty
Correction of sample size
Correction of sample size
empty
تصحیح حجم نمونه
تصحیح حجم نمونه
Intervention groups
#1
گروه مداخله: کرم واژینال ویتامین E حاوی 100 IU ویتامین E در نصف اپلیکاتور. نصف اپلیکاتور از کرم واژینال هر هفته در هفته اول و دو شب در هفته در هفته های بعد استفاده می شود.
گروه مداخله: کرم واژینال ویتامین E حاوی 100 IU ویتامین E در نصف اپلیکاتور. نصف اپلیکاتور از کرم واژینال هر شب در هفته اول و دو شب در هفته در هفته های بعد استفاده می شود.
گروه مداخله: کرم واژینال ویتامین E حاوی 100 IU ویتامین E در نصف اپلیکاتور. نصف اپلیکاتور از کرم واژینال هر هفتهشب در هفته اول و دو شب در هفته در هفته های بعد استفاده می شود.
#2
گروه کنترل: کرم واژینال استروژن کونژوگه با دوز 0.625 میلی گرم به میزان نصف اپلیکاتور که حاوی 0.3 میلی گرم استروژن کونژوگه است. نصف اپلیکاتور از کرم واژینال هر هفته در هفته اول و دو شب در هفته در هفته های بعد استفاده می شود
گروه کنترل: کرم واژینال استروژن کونژوگه با دوز 0.625 میلی گرم به میزان نصف اپلیکاتور که حاوی 0.3 میلی گرم استروژن کونژوگه است. نصف اپلیکاتور از کرم واژینال هر شب در هفته اول و دو شب در هفته در هفته های بعد استفاده می شود
گروه کنترل: کرم واژینال استروژن کونژوگه با دوز 0.625 میلی گرم به میزان نصف اپلیکاتور که حاوی 0.3 میلی گرم استروژن کونژوگه است. نصف اپلیکاتور از کرم واژینال هر هفتهشب در هفته اول و دو شب در هفته در هفته های بعد استفاده می شود
Recruitment centers
#1
Name of recruitment center - English: Tabriz city health centers
Name of recruitment center - Persian: مراکز بهداشتی شهرستان تبریز
Full name of responsible person - English: Sevil Hakimi
Full name of responsible person - Persian: سویل حکیمی
Street address - English: Sheikh Shahaboddin Street
Street address - Persian: خیابان شیخ شهاب الدین
City - English: Tabriz
City - Persian: تبریز
Province: East Azarbaijan
Country: Iran (Islamic Republic of)
Postal code: 5451674987
Phone: +98 41 4422 9993
Fax:
Email: hakimis@tbzmed.ac.ir
Web page address:
Name of recruitment center - English: Ahar city health centers
Name of recruitment center - Persian: مراکز بهداشتی درمانی شهرستان اهر
Full name of responsible person - English: Sevil Hakimi
Full name of responsible person - Persian: سویل حکیمی
Street address - English: Sheikh Shahabuddin Ave, Ahar, Iran
Street address - Persian: اهر، خیابان شیخ شهاب الدین
City - English: َAhar
City - Persian: اهر
Province: East Azarbaijan
Country: Iran (Islamic Republic of)
Postal code: 5451674987
Phone: +98 41 4422 2033
Fax:
Email: hakimis@tbzmed.ac.ir
Web page address:
Name of recruitment center - English: TabrizAhar city health centers Name of recruitment center - Persian: مراکز بهداشتی درمانی شهرستان تبریزاهر Full name of responsible person - English: Sevil Hakimi Full name of responsible person - Persian: سویل حکیمی Street address - English: Sheikh Shahaboddin StreetShahabuddin Ave, Ahar, Iran Street address - Persian: اهر، خیابان شیخ شهاب الدین City - English: TabrizَAhar City - Persian: تبریزاهر Province: East Azarbaijan Country: Iran (Islamic Republic of) Postal code: 5451674987 Phone: +98 41 4422 99932033 Fax: Email: hakimis@tbzmed.ac.ir Web page address:
Protocol summary
Study aim
Comparison of effect of vitamin E vaginal cream with vaginal estradiole on atrophic vaginitis among menopausal women.
Design
In this research, 72 eligible menopausal women who affected by atrophic vaginitis and over active bladder syndrome, referring to Tabriz health centers will be chosen and will be randomly divided into two groups of control and intervention. Group allocation will be concealed by assigning a unique code to each participants.This trial is a study in Phase zero.
Settings and conduct
The intervention group (receiving vitamin E vaginal cream containing 100 IU of vitamin E in half of the applicator) and control group (receiving conjugated estrogen vaginal cream with a dose of 0.625 mg in half of applicator containing 0.3 mg of conjugated estrogen), will use the half of the vaginal cream applicator deeply every night during the first week and two nights every week in the following weeks. The duration of the intervention will be eight weeks. The location of study will be in Tabriz health centers.
Participants/Inclusion and exclusion criteria
Menopausal women older than 45 years which having inclusion and exclusion criteria.
Intervention groups
The intervention group (receiving vitamin E vaginal cream containing 100 IU of vitamin E) and the control group (receiving conjugated estrogen vaginal cream whit a dose of 0.625 mg), half the applicator every night in the first week and in the following weeks 2 nights per week, will use for eight weeks.
Main outcome variables
Score of symptoms of atrophic vaginitis
General information
Reason for update
Correction of sample size
Acronym
IRCT registration information
IRCT registration number:IRCT20150424021917N12
Registration date:2021-06-13, 1400/03/23
Registration timing:prospective
Last update:2022-07-31, 1401/05/09
Update count:1
Registration date
2021-06-13, 1400/03/23
Registrant information
Name
Sevil Hakimi
Name of organization / entity
Tabriz University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 41 3479 6770
Email address
hakimis@tbzmed.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2021-06-22, 1400/04/01
Expected recruitment end date
2021-11-22, 1400/09/01
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Comparison of effect of vitamin E vaginal cream with vaginal estradiole on atrophic vaginitis among menopausal women.
Public title
Comparison of effect of vitamin E vaginal cream with vaginal estradiole on atrophic vaginitis among menopausal women.
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Physiologic menopause women
Having sexual activity
Affected by atrophic vaginitis(having 3 signs out of 5 signs)
Affected by over active bladder syndrome (score 3 of the OABSS questionnaire)
Exclusion criteria:
Vaginal bleeding
Hormone replacement therapy during last 3 months
History of breast cancer or any type of estrogen dependent cancer
History of breast cancer in first grade relatives (ex. mother, sister)
Estrogen contraindications include a history of gallstones, a history of venous thrombosis, any type of vascular disease, the presence of thrombophlebitis.
Taking anticoagulants
Age
From 45 years old to 56 years old
Gender
Female
Phase
2
Groups that have been masked
Participant
Investigator
Data analyser
Sample size
Target sample size:
72
Randomization (investigator's opinion)
Randomized
Randomization description
In this research, randomization will be done using random blocks size 4 and 6. Randomization will be individual randomization. For randome allocation, vitamin E vaginal cream and conjugated estrogen cream are put in opaque envelopes. On the envelopes A and B code and numbers are written. Envelops will be given to the participants respectively.
Blinding (investigator's opinion)
Triple blinded
Blinding description
In this study, participants, researcher and data analyzer will be blind. Each type of drugs will be the same according to smell, shape and color. the drugs will be accepted code A or B. This code is clarified only of drug formulation specialist. So the participants, researcher and data analyzer will be blind. After data analyzing formulation specialist will be clarified that each code of A and B belong to which group.
Placebo
Not used
Assignment
Parallel
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Ethics committee of Tabriz University of Medical Sciences
Street address
Faculty of Nursing & Midwifery, South Shariaty Street
City
Tabriz
Province
East Azarbaijan
Postal code
5138947977
Approval date
2021-05-02, 1400/02/12
Ethics committee reference number
IR.TBZMED.REC.1400.098
Health conditions studied
1
Description of health condition studied
Atrophic Vaginitis
ICD-10 code
N95.2
ICD-10 code description
Senile (atrophic) vaginitis
Primary outcomes
1
Description
Score of symptoms of atrophic vaginitis
Timepoint
Vaginal symptoms score will be measured before and 8 weeks after the start of the intervention.
Method of measurement
For evaluation of this variable we will use of standard questionnaire.
Secondary outcomes
1
Description
Score of symptoms of overactive bladder syndrome
Timepoint
Score of symptoms of overactive bladder syndrome will be measured before and 8 weeks after the start of the intervention.
Method of measurement
A standard questionnaire is used to measure this variable.
2
Description
Satisfaction score
Timepoint
Satisfaction score of the drug will be measured 8 weeks after the start of the intervention.
Method of measurement
A standard questionnaire is used to measure this variable.
3
Description
frequency of side effects
Timepoint
frequency of side effects, will be measured 8 weeks after the start of the intervention.
Method of measurement
A standard questionnaire is used to measure this variable.
Intervention groups
1
Description
Intervention group: vitamin E vaginal cream containing 100 IU of vitamin E in half of the applicator. The half of the vaginal cream applicator is used every night during the first week and two nights every week in the following weeks
Category
Treatment - Drugs
2
Description
Control group: conjugated estrogen vaginal cream with a dose of 0.625 mg in half of applicator containing 0.3 mg of conjugated estrogen. The half of the vaginal cream applicator is used every night during the first week and two nights every week in the following weeks
Category
Treatment - Drugs
Recruitment centers
1
Recruitment center
Name of recruitment center
Ahar city health centers
Full name of responsible person
Sevil Hakimi
Street address
Sheikh Shahabuddin Ave, Ahar, Iran
City
َAhar
Province
East Azarbaijan
Postal code
5451674987
Phone
+98 41 4422 2033
Email
hakimis@tbzmed.ac.ir
Sponsors / Funding sources
1
Sponsor
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Mohammad Samiei
Street address
Research department, Third floor, Central construction, Number 2, Tabriz medical science university, Golgasht Street, Azadi Avenue, Tabriz
City
Tabriz
Province
East Azarbaijan
Postal code
5138947977
Phone
+98 41 3335 7310
Email
Samiei.moh@gmail.com
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
No
Title of funding source
Tabriz University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic
Person responsible for general inquiries
Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Sevil Hakimi
Position
Associate professor
Latest degree
Ph.D.
Other areas of specialty/work
Midwifery
Street address
Faculty of Nursing & Midwifery, South Shariaty Street
City
Tabriz
Province
East Azarbaijan
Postal code
5138947977
Phone
+98 4134790364 - 34796770
Email
hakimisevil@gmail.com
Person responsible for scientific inquiries
Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Sevil Hakimi
Position
Associate professor
Latest degree
Ph.D.
Other areas of specialty/work
Midwifery
Street address
Faculty of Nursing & Midwifery, South Shariaty Street
City
Tabriz
Province
East Azarbaijan
Postal code
5138947977
Phone
+98 4134790364 - 34796770
Email
hakimisevil@gmail.com
Person responsible for updating data
Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Sevil Hakimi
Position
Associate professor
Latest degree
Ph.D.
Other areas of specialty/work
Midwifery
Street address
Faculty of Nursing & Midwifery, South Shariati Street
City
Tabriz
Province
East Azarbaijan
Postal code
5138947977
Phone
+98 4134790364 - 34796770
Fax
+98 41 3479 6969
Email
hakimisevil@gmail.com
Sharing plan
Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
No - There is not a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Yes - There is a plan to make this available
Data Dictionary
No - There is not a plan to make this available
Title and more details about the data/document
Primary and secondary outcomes, as well as side events will be distributed.
When the data will become available and for how long
Six months after publication of results.
To whom data/document is available
Records will be distributed of academic researchers and " research and development" units of pharmaceutical companies.
Under which criteria data/document could be used
" Research and development" unit of each pharmaceutical companies can use of records. All requests will be evaluated after receiving formal e- mail and telephone or face to face negotiation.
From where data/document is obtainable
Sevil Hakimi hakimis@tbzmed.ac.ir
What processes are involved for a request to access data/document
The applicant notifies the applicant by email, after receiving the email the results are sent.